FAM168B

Across TCGA pan-cancer cohorts, FAM168B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM168B data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher FAM168B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM168B expression acts as an unfavorable survival marker.

KIRP, SKCM, and LIHC are the cancer types where FAM168B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.141	0.904	<.001	36	view →
SKCM	DFS	Median	All	0.058	0.728	<.001	15	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	9	view →
BRCA	OS	Median	All	0.175	0.579	.026	8	view →
UCEC	OS	Median	IV	0.277	0.605	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM168B–KIRP (OS)

Open the KIRP breakdown →